drug_type
RELEVANT_DRUG
intervention_type
Autologous gene-modified cellular immunotherapy (CAR T cells)
drug_description
Autologous gene-modified T lymphocytes engineered to express a chimeric antigen receptor that recognizes CD19 and targets within the BAFF (BLyS) axis (e.g., BAFF-R/TACI/BCMA), enabling activation and cytolytic depletion of pathogenic B cells/plasmablasts to reduce BCR signaling, germinal center activity, and autoantibody production in refractory autoimmune disease.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered with a chimeric antigen receptor that recognizes CD19 and BAFF-axis receptors (BAFF-R/TACI/BCMA), leading to antigen-dependent activation and cytolytic elimination of B cells and plasmablasts. This depletes pathogenic B-lineage cells, disrupts BAFF-mediated survival signals, and reduces BCR signaling, germinal center activity, and autoantibody production in autoimmune disease.
drug_name
CD19-BAFF-targeted CAR T cells
nct_id_drug_ref
NCT06279923